Login / Signup

Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.

Jaume MoraAlicia CastañedaMaite GorosteguiVicente Santa-MaríaMoira GarrausJuan Pablo MuñozAmalia VaroSara Perez-JaumeSalvador Mañe
Published in: Pediatric blood & cancer (2021)
Consolidation with naxitamab and GM-CSF resulted in excellent survival rates for HR-NB patients in CR.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • adipose tissue
  • patient reported outcomes
  • systemic lupus erythematosus
  • disease activity
  • patient reported